Total submissions: 9
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Center for Bioinformatics, |
RCV000180917 | SCV000221893 | pathogenic | Severe myoclonic epilepsy in infancy | 2014-12-20 | criteria provided, single submitter | research | |
Gene |
RCV000423099 | SCV000514487 | pathogenic | not provided | 2024-08-08 | criteria provided, single submitter | clinical testing | Nonsense variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss of function is a known mechanism of disease; Not observed at significant frequency in large population cohorts (gnomAD); This variant is associated with the following publications: (PMID: 25525159, 17054684, 27465585, 30182498, 30321769, 26096185, 31009440, 30868114, 23808377, 30641252, 32090326, 33278787, 32427350, 31440721, 31031587, 28664031, 35074891, 36480001, 36801247) |
Labcorp Genetics |
RCV000529401 | SCV000633808 | pathogenic | Early infantile epileptic encephalopathy with suppression bursts | 2023-10-13 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Arg377*) in the SCN1A gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SCN1A are known to be pathogenic (PMID: 17347258, 18930999). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with Dravet syndrome (PMID: 17054684, 23808377, 27465585). In at least one individual the variant was observed to be de novo. ClinVar contains an entry for this variant (Variation ID: 189963). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic. |
Ce |
RCV000423099 | SCV001501315 | pathogenic | not provided | 2020-07-01 | criteria provided, single submitter | clinical testing | |
Neuberg Centre For Genomic Medicine, |
RCV000180917 | SCV002820213 | pathogenic | Severe myoclonic epilepsy in infancy | criteria provided, single submitter | clinical testing | The stop gained variant c.1129C>T(p.Arg377Ter) in SCN1A gene has been reported previously in individuals affected with Dravet syndrome (Djémié et al., 2016). This variant has been reported to the ClinVar database as Pathogenic. The p.Arg377Ter variant is novel (not in any individuals) in gnomAD Exomes and 1000 Genomes. The nucleotide change in SCN1A is predicted as conserved by GERP++ and PhyloP across 100 vertebrates. This variant is predicted to cause loss of normal protein function through protein truncation. Loss-of-function variants in SCN1A are known to be pathogenic (Harkin et al., 2007; Depienne et al., 2009). For these reasons, this variant has been classified as Pathogenic. | |
Diagnostic Laboratory, |
RCV000423099 | SCV001742868 | pathogenic | not provided | no assertion criteria provided | clinical testing | ||
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, |
RCV000423099 | SCV001953968 | pathogenic | not provided | no assertion criteria provided | clinical testing | ||
Génétique des Maladies du Développement, |
RCV000180917 | SCV002538990 | pathogenic | Severe myoclonic epilepsy in infancy | no assertion criteria provided | clinical testing | ||
Diagnostic Laboratory, |
RCV002274946 | SCV002562850 | likely pathogenic | Seizure | no assertion criteria provided | clinical testing |